Clinical Trial Update: Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas [NA]

View source ↗

Summary

A recruiting study evaluating the feasibility and clinical utility of circulating cell-free DNA to identify actionable alterations and minimal residual disease …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | NA | Status: RECRUITING